Crown Bioscience November 2022 Newsletter
Welcome to the new monthly Crown Bioscience newsletter. Discover some of our November highlights below to keep up to date with our recent developments, and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!
Biomarker-driven clinical trials have higher success rates, due to their accurate targeting ability. Our webinar will use case studies to demonstrate how to identify potential biomarkers at the preclinical study stage using better experimental design and powerful bioinformatics data analysis.
Empower your lead identification search with targeted statistical analysis that moves beyond standard IC50 readouts to structural investigations of your candidates.
Translate your IBD therapeutics to the clinic with our well characterized in vivo models to understand the preclinical efficacy of Crohn’s disease (CD) and ulcerative colitis (UC) agents.
Our new blog post explores how to leverage Patient-Derived Xenograft (PDX) models for modeling metastatic breast cancer, including models that spontaneously recapitulate the clinical metastatic process.
Watch our on-demand webinar to learn about the current therapeutic landscape of breast cancer and which models and strategies are best to use for preclinical studies targeting advanced breast cancers.
Our colleagues in San Diego were delighted to support the Making Strides Against Breast Cancer charity walk on 16 October, which was held to raise awareness of early detection in saving lives.
Screen your compound across well validated panels of in vivo Syngeneic Efficacy and PD Mode or Tumor Homograft Efficacy Mode to accelerate your drug development. New dates are now available.
© 2022 Crown Bioscience, Inc.
Crown Bioscience, Inc.16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States